The European Commission has approved Chiesi’s Trimbow extrafine beclometasone / formoterol / glycopyrronium MDI for the treatment of asthma in patients who do not have adequate control with ICS/LABA and who have had at least one exacerbation over the previous year. In October 2019, Chiesi announced positive results from the Phase 3 TRIGGER and TRIMARAN studies of the triple combination in asthma patients. Trimbow has been approved for the treatment of COPD in patients without adequate control with ICS/LABA in the EU since 2017.
Chiesi Group Chief Commercial Officer Alessandro Chiesi commented, “This is the first step towards taking our triple therapy for moderate to severe COPD patients and providing the same treatment option for appropriate asthma patients. Chiesi is committed to developing and delivering alternatives to aid patients in the management of their respiratory conditions and treatment. The European Commission’ approval brings us one step closer to providing uncontrolled adult asthma patients with a new treatment option for their care, reducing exacerbations and potentially simplifying the use for patients, thanks to a single inhaler triple therapy.”
Read the Chiesi press release.
